Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
Date:11/4/2009

Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals® and Arena® are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; regulatory authorities may not find data from Arena's clinical trials and studies sufficient for regulatory approval; the timing and ability of Arena to receive regulatory approval for its drug candidates; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or oblig
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) ... received a written notice (the "Notice") executed by the ... of the Company, requesting that the Board of Directors ... for stockholder action by written consent relating to the ... director seat resulting from Ronald J. Kanterman,s departure (the ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... KNOXVILLE, Tenn., Dec. 15 Medical researchers ... attention with their revolutionary new technology for a ... ,, Following the success of its ... filed a patent on the biomarker, CA11-19, and ... inexpensive blood test, ColoMarker(TM) will detect colon cancer ...
Breaking Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2Stanford study recommends change in treating pulmonary embolisms 60161 1Stanford study recommends change in treating pulmonary embolisms 60161 2Stanford study recommends change in treating pulmonary embolisms 60161 3Stanford study recommends change in treating pulmonary embolisms 60161 4Vegetables can protect unborn child against diabetes 10545 1Vegetables can protect unborn child against diabetes 10545 2Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 1Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 2
(Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... 16 /PRNewswire-FirstCall/ - TSO3 Inc. ("TSO3") (TSX: TOS) ... has been reached for 3M to be the ... Sterilizer. The partnership with TSO3, an innovator in ... healthcare settings through the use of ozone, will ... through 3M,s global sales channel. This agreement, combined ...
(Date:12/16/2009)... engaged in the development of products that help survivors of ... mobility, announces the publication of an interview with the inventors ... (Advance for Physical Therapy and Rehab Medicine, vol. 20, issue ... , ... (PRWEB) December 16, 2009 -- ...
(Date:12/16/2009)... of buying another product or thing for your loved ones this ... personal assistant services like housekeeping, errand running, child care, and pet ... ... December 12, 2009 -- Residents of the Denver and Boulder metro ... to their friends and loved ones by using Delegate Source,s " ...
Breaking Medicine News(10 mins):Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 3
... emission tomography (PET) imaging with bioluminescencethe light produced by ... understand the behavior of transplanted or implanted stem cells ... treatments for disease. , According to a study ... found that using the unique combination of noninvasive PET ...
... 6 A Canadian research team led by ... Columbia, Vancouver has,determined that there are significant changes ... instead of a standard exercise bicycle.,This research offers ... date on,the positive health and fitness effects of ...
... Medicaid Generic Prescription,Drug System, FRANKFORT, Ky., Dec. ... press conference at Capital Pharmacy and,Medical Equipment urging ... ensure S.1951, the Fair Medicaid Drug Payment Act ... a vote before they adjourn this year.,The bill ...
... ready to attend,holiday parties, it,s time for parents to ... alcohol. Teens are constantly exercising their,independence and individuality, and ... chances are your teens will be too., Even ... guarantees.,According to a study last year by The National ...
... busiest shopping time of the year. In fact, more than ... this year according to a survey by the National Retail ... to the shopping trends. , One such economist, Dr. ... author of The Personality Continuum and Consumer Behavior, has taken ...
... Medical research has revealed much about cancer prevention, but ... acting on it" Today, at the American Association ... in Cancer Prevention Research, being held from December 5 ... of how best to translate cancer prevention science into ...
Other Medicine News:Health News:PET and bioluminescent imaging aid evaluation of stem cells' potential for new ways to treat disease 2Health News:PET and bioluminescent imaging aid evaluation of stem cells' potential for new ways to treat disease 3Health News:University of British Columbia Research Shows Health Benefits of GameBike (TM) 2Health News:Kentucky Pharmacists Urge Senator McConnell to Put Patients First 2Health News:Kentucky Pharmacists Urge Senator McConnell to Put Patients First 3Health News:This Holiday Season, Teach Your Kids the Science of How Drinking Alcohol Can Hurt Them 2Health News:This Holiday Season, Teach Your Kids the Science of How Drinking Alcohol Can Hurt Them 3Health News:Public health and cancer prevention: Success and future challenges in cancer policy 2Health News:Public health and cancer prevention: Success and future challenges in cancer policy 3Health News:Public health and cancer prevention: Success and future challenges in cancer policy 4Health News:Public health and cancer prevention: Success and future challenges in cancer policy 5Health News:Public health and cancer prevention: Success and future challenges in cancer policy 6Health News:Public health and cancer prevention: Success and future challenges in cancer policy 7
Hypervisor III Central Monitoring System...
... Central Monitoring System combines Invivo's AutoNet™ ... central monitoring and clinical information system ... monitoring features, including alarms, full disclosure ... connecting your patient to a bedside ...
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... List Editor) Multi-Channel Infusion System brings a ... instrument combines three independent infusion channels with ... unparalleled small size. Now with Advanced Dose ... simplifies the delivery of complex drug regimens. ...
Medicine Products: